{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:48:17Z","timestamp":1785437297277,"version":"3.56.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:p>\n                    A retrospective study was conducted to analyze changes in the diagnosis, treatment, and prognosis of multiple myeloma (MM) patients in a provincial medical center in the Gannan region and to describe the gradual improvements in these methods. The clinical data of patients with newly diagnosed multiple myeloma (NDMM) at the First Affiliated Hospital of Gannan Medical University from January 1, 2013, to December 31, 2022, were retrospectively collected. Demographic and clinical characteristics, 1st-line treatment and its efficiency, survival, and prognostic factors of patients with MM in the past 10 years were analyzed. A total of 439 patients with NDMM were identified, with a median age of 64 (33\u201391) years and a male-to-female ratio of approximately 1.26:1. Among the patients, 56.95% were classified as International Staging System stage III. A total of 168 patients (38.27%) underwent fluorescence in situ hybridization, with a positive rate of 68.45%. The proportion of patients who underwent autologous stem cell transplantation was low. The main regimen used for induction therapy was proteasome inhibitor\u2005+\u2005immunomodulatory drug-based triple chemotherapy. During follow-up, the overall response rate was 72.73%, and the complete response rate was 20.35%. The short-term and long-term overall survival (OS) rates increased annually. The median OS was 1273 days, and the 5-year OS% was 35.70%. Multivariate Cox analysis revealed that age\u2005&gt;\u200565 years; no autologous stem cell transplantation; progression to relapsed and refractory MM; and increased lactate dehydrogenase, \u03b2\n                    <jats:sub>2<\/jats:sub>\n                    -microglobulin, and uric acid levels were independent poor prognostic factors affecting OS. In the past decade, the diagnosis of NDMM and treatment methods in the Gannan area have gradually improved. With the popularization of new technologies and the widespread use of standardized treatment regimens containing new drugs, the short-term and long-term survival of MM patients in the Gannan area has significantly improved.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047332","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:00:22Z","timestamp":1769191222000},"page":"e47332","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Changes in the diagnosis, treatment, and prognosis of multiple myeloma in southern Jiangxi Province from 2012 to 2022"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3546-1480","authenticated-orcid":false,"given":"Qi","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Hematology, The Endemic Disease (Thalassemia) Clinical Research Center of Jiangxi Province, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingfang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Endemic Disease (Thalassemia) Clinical Research Center of Jiangxi Province, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunwang","family":"Liang","sequence":"additional","affiliation":[{"name":"School of Medical Technology, Gannan Medical University, Ganzhou, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"School of the First Clinical Medicine, Gannan Medical University, Ganzhou, Jiangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiqing","family":"Rao","sequence":"additional","affiliation":[{"name":"School of the First Clinical Medicine, Gannan Medical University, Ganzhou, Jiangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhe","family":"Zhu","sequence":"additional","affiliation":[{"name":"School of the First Clinical Medicine, Gannan Medical University, Ganzhou, Jiangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8698-6215","authenticated-orcid":false,"given":"Zoufang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Endemic Disease (Thalassemia) Clinical Research Center of Jiangxi Province, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260610","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma.","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"R2-20260610","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, Version 2.2024, NCCN clinical practice guidelines in oncology.","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"R3-20260610","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"15_suppl","key":"R4-20260610","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2021.39.15_suppl.8002","article-title":"Carfilzomib-based induction\/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients.","volume":"39","author":"Gay","year":"2021","journal-title":"J Clin Oncol"},{"key":"R5-20260610","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3324\/haematol.2013.083592","article-title":"Multiple myeloma: so much progress, but so many unsolved questions.","volume":"98","author":"Moreau","year":"2013","journal-title":"Haematologica"},{"key":"R6-20260610","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1080\/10428194.2021.1924369","article-title":"Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens.","volume":"62","author":"Zamagni","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"R7-20260610","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.1182\/blood-2024-201167","article-title":"Analysis of diagnosis and treatment pattern for newly diagnosed multiple myeloma in china over 20 Years.","volume":"144","author":"Xu","year":"2024","journal-title":"Blood"},{"key":"R8-20260610","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1053\/j.seminoncol.2021.11.003","article-title":"Managing multiple myeloma in a resource-limited region: diagnosis and treatment in Armenia.","volume":"48","author":"Oganesyan","year":"2021","journal-title":"Semin Oncol"},{"key":"R9-20260610","doi-asserted-by":"crossref","first-page":"9604","DOI":"10.1002\/cam4.5737","article-title":"The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years\u2019 experience of 1256 patients in a national medical center.","volume":"12","author":"Yang","year":"2023","journal-title":"Cancer Med"},{"key":"R10-20260610","doi-asserted-by":"crossref","first-page":"1554485","DOI":"10.3389\/fpubh.2025.1554485","article-title":"Long-term trends in the burden of multiple myeloma in China: a Joinpoint regression and age-period-cohort analysis based on GBD 2021.","volume":"13","author":"Zhang","year":"2025","journal-title":"Front Public Health"},{"key":"R11-20260610","doi-asserted-by":"crossref","first-page":"217440","DOI":"10.1016\/j.canlet.2025.217440","article-title":"The burden of multiple myeloma in China: trends from 1990 to 2021 and forecasts for 2050.","volume":"611","author":"Dou","year":"2025","journal-title":"Cancer Lett"},{"key":"R12-20260610","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma.","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"R13-20260610","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ajh.25657","article-title":"Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients.","volume":"95","author":"Al Saleh","year":"2020","journal-title":"Am J Hematol"},{"key":"R14-20260610","first-page":"794","article-title":"The value of sFLC and serum calcium in the diagnosis and prognosis of multiple myeloma patients.","volume":"32","author":"Pei","year":"2024","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"R15-20260610","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma.","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"R16-20260610","first-page":"12","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R17-20260610","first-page":"7","article-title":"Cancer statistics, 2020.","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R18-20260610","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3389\/fonc.2019.01513","article-title":"Prevalence and incidence of multiple myeloma in Urban area in China: a national population-based analysis.","volume":"9","author":"Wang","year":"2019","journal-title":"Front Oncol"},{"key":"R19-20260610","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1038\/bcj.2014.55","article-title":"Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis.","volume":"4","author":"Lu","year":"2014","journal-title":"Blood Cancer J"},{"key":"R20-20260610","doi-asserted-by":"crossref","first-page":"668099","DOI":"10.3389\/fonc.2021.668099","article-title":"Multiple extramedullary-bone related and\/or extramedullary extraosseous are independent poor prognostic factors in patients with newly diagnosed multiple myeloma.","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol"},{"key":"R21-20260610","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1186\/s12885-020-07178-5","article-title":"Education level as a predictor of survival in patients with multiple myeloma.","volume":"20","author":"Xu","year":"2020","journal-title":"BMC Cancer"},{"key":"R22-20260610","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clml.2020.11.020","article-title":"Impact of socioeconomic characteristics and comorbidities on therapy initiation and outcomes of newly diagnosed multiple myeloma: real-world data from a resource-constrained setting.","volume":"21","author":"Vargas-Serafin","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R23-20260610","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1038\/s41409-021-01431-6","article-title":"Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group.","volume":"56","author":"Xu","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R24-20260610","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3892\/ol.2012.1018","article-title":"Retrospective analysis of 264 multiple myeloma patients.","volume":"5","author":"Geng","year":"2013","journal-title":"Oncol Lett"},{"key":"R25-20260610","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1038\/s41409-021-01308-8","article-title":"Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).","volume":"56","author":"Bergin","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R26-20260610","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00277-021-04481-4","article-title":"Characteristics and survival trends in Finnish multiple myeloma patients-a nationwide real-world evidence study.","volume":"100","author":"Toppila","year":"2021","journal-title":"Ann Hematol"},{"key":"R27-20260610","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"R28-20260610","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/leu.2013.220","article-title":"Association of response endpoints with survival outcomes in multiple myeloma.","volume":"28","author":"Lonial","year":"2014","journal-title":"Leukemia"},{"key":"R29-20260610","doi-asserted-by":"crossref","first-page":"77","DOI":"10.20892\/j.issn.2095-3941.2022.0612","article-title":"Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study.","volume":"20","author":"Fan","year":"2023","journal-title":"Cancer Biol Med"},{"key":"R30-20260610","first-page":"180","article-title":"Value of systemic immune-inflammation index in the prognostic evaluation of newly diagnosed multiple myeloma patients.","volume":"35","author":"Juan","year":"2022","journal-title":"J Clin Hematol"},{"key":"R31-20260610","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma.","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J"},{"key":"R32-20260610","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib\u2013lenalidomide\u2013dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study.","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"R33-20260610","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/10245332.2015.1101969","article-title":"Early mortality in multiple myeloma: Experiences from a single institution.","volume":"21","author":"Chen","year":"2016","journal-title":"Hematology"},{"key":"R34-20260610","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends.","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:00:50Z","timestamp":1781085650000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047332","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"2025-09-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}